Scarica l'app Stockscreener
2.22
0.45%
-0.010
Dopo l'orario di chiusura:
2.25
0.03
+1.35%
Precedente Chiudi:
$2.23
Aprire:
$2.24
Volume 24 ore:
491.70K
Relative Volume:
0.57
Capitalizzazione di mercato:
$141.38M
Reddito:
-
Utile/perdita netta:
$-30.92M
Rapporto P/E:
-3.6822
EPS:
-0.6029
Flusso di cassa netto:
$-27.39M
1 W Prestazione:
+6.73%
1M Prestazione:
-3.90%
6M Prestazione:
+155.17%
1 anno Prestazione:
-9.39%
Intervallo 1D:
$2.19
$2.38
Intervallo di 1 settimana:
$2.07
$2.4843
Portata 52W:
$0.41
$3.90
Tuhura Biosciences Inc Stock (HURA) Company Profile
Nome
Tuhura Biosciences Inc
Settore
Industria
Telefono
813-875-6600
Indirizzo
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.22 | 144.56M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Citizens | Mkt Outperform |
| 2025-03-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-19 | Iniziato | Rodman & Renshaw | Buy |
| 2024-11-05 | Iniziato | Maxim Group | Buy |
Tuhura Biosciences Inc Borsa (HURA) Ultime notizie
Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com - Investing.com Canada
TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025 - grafa.com
TuHURA files IND for TBS-2025 in blood cancer study - Investing.com
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers - PR Newswire
TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates, Stock Rises Despite Wider Loss - newsline.com
HURA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Stage; Stock Gains 5.29%Margin Expansion Trends - newsline.com
TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Risk Report - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Miss Highlights Pre-Revenue Biotech's Expense Management ChallengesSurprise Factor Analysis - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseMargin Improvement Report - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates, Stock Slides on Higher Cash Burn and Pre-Revenue StatusRevenue Miss Report - newsline.com
HURA News | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq Listing Details and Company Information - Minichart
TuHURA Biosciences Draws on New $50M Credit Facility - TipRanks
TuHURA (NASDAQ: HURA) taps $1.7M from $50M revolving loan facility - Stock Titan
TuHURA Biosciences (HURA) CEO James Bianco gifts 150,000 shares to adult sons - Stock Titan
HURA: Refining TBS-2025 Development Plan - Yahoo Finance
TuHURA Biosciences Inc. (HURA) Rises 6.84% as Price Tests Key Resistance LevelTriangle Correction - newsline.com
TuHURA Biosciences Inc. Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineGuidance vs Actual - newsline.com
TuHURA Biosciences (HURA) Gains Nearly 7% as Shares Approach Key Resistance at $2.62Synthetic Short - Newser
Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks - The Globe and Mail
TuHURA Biosciences Secures $50M Credit Facility and Reports Q1 2026 Financial Results, Advancing Phase 3 Immuno-Oncology Programs - Minichart
TuHURA Biosciences Extends Cash Runway and Advances Pipeline - TipRanks
TuHURA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary - TradingView
TuHURA Biosciences (HURA) adds $50M credit line amid $7.5M loss - Stock Titan
TuHURA Biosciences (Nasdaq: HURA) secures $50M credit facility and outlines Q1 2026 pipeline milestones - Stock Titan
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences, Inc. (HURA) Eps Diluted (TTM) - Zacks Investment Research
HURA Stock Chart | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - ChartMill
TradingKey - TradingKey
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Number of shareholders of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
Why TuHURA Biosciences (HURA) is trading below its true worth (Trend Weakens) 2026-05-08Beta Neutral Pair - newsline.com
Tuhura Biosciences, Inc. 2025 Annual Report: Financial Results, Research & Development Expenses, and Key Business Highlights - Minichart
HURA Should I Buy - Intellectia AI
TuHURA Biosciences (NASDAQ: HURA) updates Kineta merger pro forma loss to $34.6M - Stock Titan
TuHURA Biosciences (NASDAQ: HURA) details 2025 loss and cash runway - Stock Titan
HURA TuHURA Biosciences Q4 2025 EPS trails estimates by 28.2 percent, shares slip 1.41 percent in today’s trading. - newsline.com
Citizens initiates TuHURA Biosciences stock with outperform rating By Investing.com - Investing.com South Africa
Citizens initiates TuHURA Biosciences stock with outperform rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP By Investing.com - Investing.com Nigeria
Tuhura Biosciences secures $50 million credit facility, extends cash runway to 2028 - MSN
TuHURA Biosciences secures $50M credit facility from affiliate By Investing.com - Investing.com India
HURA (TuHURA Biosciences Inc.) posts 28.2 percent negative Q4 2025 EPS surprise, with shares falling 1.35 percent today.Community Risk Signals - UBND thành phố Hải Phòng
TuHURA Biosciences secures $50M credit facility from affiliate - Investing.com
TuHURA Biosciences Secures $50 Million Credit Facility - TipRanks
TuHURA Biosciences (Nasdaq: HURA) adds $50M credit line and IFx-2.0 royalty - Stock Titan
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - PR Newswire
Tuhura Biosciences Inc Azioni (HURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):